Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...
Sangamo Therapeutics ( NASDAQ:SGMO ) Third Quarter 2022 Results Key Financial Results Revenue: US$26.5m (down 7.4% from...
Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?